EQS-Adhoc: Biotest AG: Delisting agreement and announced delisting purchase offer

Ad hoc

Notification according to Art. 17 EU market abuse regulation (Mar)

Dreieich, March 31, 2025: Biotest AG (ISIN DE000527201, ISIN DE0005227235) has now completed a delisting agreement with its major shareholder, Grifols, SA, the approximately 97.14 % of the regular shares and 46.22 % of the preferred stocks of Biotest AG.

On the basis of this delisting agreement, the position of an application for the revocation of the admission of the Biotest Stem shares and the Biotest preferred shares for trading in the regulated market (Prime Standard) of the Frankfurt Storage Exchange (so-called delisting) by the board of Biotest AG. In addition, Biotest AG will take all reasonable measures in order to end the inclusion of the biotest stem shares and the Biotest preferred shares in free transport, insofar as this included in the request of Biotest AG.

According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100 percent subsidiary of Grifols, SA the shareholders of Biotest AG is an absolute public delisting acquisition offer to acquire all regular and preferred shares of Biotest AG, which are not already kept by Grifols Biotest Holdings GmbH, against payment in cash in cash 43.00 per biotest stem share and € 30.00 per biotest preferred share subject to adjustments based on legal provisions. The advance and the supervisory board will carefully examine the offer document for the public delisting acquisition offer and, in accordance with § 27 of the securities acquisition and takeover law, will provide a common justified statement.

The delisting agreement contains provisions that the Grifols. SA intends to support Biotest AG in an economically appropriate manner.

After the revocation of the stock exchange approval, the stocks of Biotest AG will no longer be approved for trading in a domestic regulated market or a comparable market abroad.

Biotest Aktiengesellschaft
The board

Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com

Disclaimer

This document contains future-oriented statements about the overall economic development as well as for business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on the current plans, assessments, forecasts and expectations of the company and are subject to risks and uncertainty factors that can lead to the fact that the actual development deviates significantly from the expected development. The future -oriented statements are only valid at the time of publication. Biotest does not intend to update the future -oriented statements and assume no obligation.

About biotest

Biotest is a provider of biological drugs that are obtained from human plasma. With a value chain that extends from pre-clinical and clinical development to global marketing, Biotest specializes primarily in the areas of application clinical immunology, hematology and intensive and emergency medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin, which are produced on the basis of human blood plasma and are used for diseases of the immune system or the blood -forming systems. Biotest employs more than 2,500 people worldwide. The main and preferred shares of Biotest AG are listed in the prime standard of the German stock exchange. Biotest has been part of the Grifols Group, Barcelona, ​​Spain (www.grifols.com) since May 2022.

Ir contact:

Dr. Monika Baumann (Buttkereit)
Telephone: +49-6103-801-4406
Email: [email protected]

PR Contact:

Dirk Neumüller
Telephone: +49-6103-801-269
Email: [email protected]

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Chief share: WKN: 522720; ISIN: DE0005227201
Preferences: WKN: 522723; ISIN: DE0005227235
Noted: Frankfurt (Prime Standard)
Free traffic: Berlin, Düsseldorf, Hamburg/ Hannover, Munich, Stuttgart, Tradegate

Contact:
Peter Janssen
CEO
Biotest AG
Landsteinerstr. 5
63303 Dreieich
Tel. +49 6103 801 1229
Fax: +6103 801 767
[email protected]